Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 5/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TACR2 | P21452 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20777212 | 1.00 | NPC1 (0.55) | NPC1RAB9ACTSLCTSSCTSK | |
| SCHEMBL20777169 | 0.91 | CTSL (0.49) | NPC1RAB9ACTSLCTSSCTSK | |
| SCHEMBL20777178 | 0.90 | CTSL (0.52) | CTSLCTSSCTSKCTSBPIN1 | |
| SCHEMBL20777199 | 0.90 | CTSL (0.52) | CTSLCTSSCTSKCTSBPIN1 | |
| SCHEMBL20777202 | 0.90 | CTSL (0.52) | CTSLCTSSCTSKCTSBPIN1 | |
| SCHEMBL24119968 | 0.86 | NPC1 (0.60) | NPC1RAB9ACTSLCTSSCTSK | |
| SCHEMBL20777173 | 0.86 | NPC1 (0.60) | NPC1RAB9ACTSLCTSSCTSK | |
| SCHEMBL20777175 | 0.83 | CTSL (0.47) | CTSLCTSSCTSKCTSBPIN1 | |
| SCHEMBL22822786 | 0.83 | NPC1 (0.48) | NPC1RAB9ACTSLMAPT | |
| SCHEMBL22823038 | 0.83 | CTSL (0.47) | CTSLCTSSCTSKCTSBPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NPC1 1443/4885RAB9A 1223/4885CTSL 4334/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NPC1 1443/4885RAB9A 1223/4885CTSL 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.